|Grant Number:||5R21CA137014-02 Interpret this number|
|Primary Investigator:||Joseph, Anne|
|Organization:||University Of Minnesota|
|Project Title:||Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure|
DESCRIPTION (provided by applicant): Smoking and secondhand smoke (SHS) are responsible for nearly a half-million preventable deaths in the United States every year. Parent(s) who stop smoking incur health benefits, model non-smoking (and quitting) to children and stop exposure to SHS in the home, car and other locations. National initiatives from the American Academy of Pediatrics and the American Academy of Family Physicians urge healthcare providers to screen children for a history of SHS exposure and to recommend that parents stop smoking and restrict smoking at home, but compliance with these guidelines is poor and more than 25% of children in the U.S. continue to be involuntarily exposed to SHS in the home. Effective systems are needed to increase parental smoking cessation and implement home smoking restrictions. We propose preliminary studies to evaluate a novel intervention to accomplish these objectives. We hypothesize that a clinic system that routinely measures and reports levels of tobacco toxicants (tobacco-specific carcinogens, nicotine and cotinine) found in the urine of children exposed to SHS will 1) increase provider delivery of tobacco treatment, 2) increase parental participation in tobacco treatment, 3) increase parental smoking cessation and 4) reduce childhood exposure to secondhand smoke. We propose formative work among healthcare providers and parents to develop the intervention and to pilot test the effects of the intervention on providers and parents. We will conduct focus groups among staff to identify training needs, develop methods to integrate the intervention with office practice and assess barriers to implementation. We will also conduct focus groups among parents to assess willingness to provide urine specimens, optimal feedback format and reactions to biomarker data. Results from focus groups will be used to develop the experimental treatment protocol. We will test the intervention in a two-group randomized pilot study in the University of Minnesota Primary Care Clinic. We will recruit 80 children age 0-12 with a parent who smokes. We will provide brief behavioral counseling in healthy lifestyle options to all parents. One provider team will implement the experimental intervention in 40 parent-child pairs and the other team will serve as the control. Children who see providers in the experimental group will provide a urine sample to test for nitrosamines (a tobacco-specific carcinogen), nicotine and cotinine. We will communicate laboratory results to providers using the electronic medical record and incorporate these results in parental tobacco counseling designed to promote smoking cessation and home smoking restrictions. The primary outcome will be provider delivery of smoking cessation treatment. We will also measure effects on parental engagement in treatment, smoking cessation and institution of home smoking restrictions in both the experimental and control groups. The research team brings extensive experience with novel tobacco interventions, health services research and biomarker assessment to the project. Routine documentation of tobacco toxicants in children's urine has potential to dramatically alter clinical care for families at risk from smoking. PUBLIC HEALTH RELEVANCE: This project tests the effect of demonstrating tobacco toxicants in the urine of children exposed to secondhand smoke on provider and parent behavior. The intervention is designed to help parents stop smoking and reduce childhood exposure to secondhand smoke.
A pilot study of concurrent lead and cotinine screening for childhood tobacco smoke exposure: effect on parental smoking.
Authors: Joseph A, Murphy S, Thomas J, Okuyemi KS, Hatsukami D, Wang Q, Briggs A, Doyle B, Winickoff JP
Source: Am J Health Promot, 2014 May-Jun;28(5), p. 316-20.
EPub date: 2013 Aug 23.
|NCI NIH HHS - R21 CA137014||NCI NIH HHS - R21CA137014|